Foreland Pharma
- Biotech or pharma, therapeutic R&D
Clinical-Stage China Biotech Seeking Partnership for First-in-Class Dual PI3Ka/DDR Inhibitor – FP-208
- A clinical-stage China biotech is seeking partners for FP-208, a novel, first-in-class small molecule currently in Phase 1（Ph1A completed）that selectively inhibits both PI3Ka and DDR (ATR, ATM, DNA-PK) pathways. Many tumors depend on PI3K/mTOR signaling for survival and growth, while DDR pathways protect against replication stress and genomic instability. These pathways are interconnected and compensate for each other—creating exploitable vulnerabilities in cancer cells.
- FP-208’s dual inhibition strategy uniquely targets the cross-talk and co-dependencies between PI3K and DDR, offering potential advantages in tumors with PIK3CA mutations, ATM or BRCA loss, MYC-driven replication stress, or resistance to PARP inhibitors via homologous recombination (HR) restoration.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}